We've got news for you.

Register on Sunday Times at no cost to receive newsletters, read exclusive articles & more.
Register now

Huge breakthrough for oncology as scientists nail lung-cancer ...


Huge breakthrough for oncology as scientists nail lung-cancer gene

For 40 years researchers have tried to block a mutant gene. They’ve now done so with a drug the FDA has approved

Robert Langreth and Fiona Rutherford

Amgen’s lung-cancer treatment sotorasib has won approval from US regulators, becoming the first therapy to target a tumour-stoking genetic mutation scientists have tried to block for decades.

The Food and Drug Administration (FDA) clearance, while only for a small group of patients, is a milestone for oncology. The drug is the first to directly target a mutant gene called KRAS G12C that’s present in about 13% of non-small-cell lung cancers.

KRAS is a growth-promoting gene that’s mutated in numerous lung, colon and pancreatic tumours. The mutations cause a key protein to send constant signals for cells to grow and proliferate...

This article is free to read if you register or sign in.

Sunday Times Daily

If you have already registered or subscribed, please sign in to continue.

Questions or problems?
Email helpdesk@timeslive.co.za or call 0860 52 52 00.

Previous Article